CCO Infectious Disease Podcast

COVID-19 Update: Independent Conference Coverage of ECCMID 2023

Episode Summary

Hear from Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI, on the latest data on COVID-19 presented at ECCMID 2023, including treatment in special populations, management of patients with severe illness, and novel antivirals and vaccines in the pipeline.

Episode Notes

In this episode, Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI, discusses new data on COVID-19 presented at ECCMID 2023, including:

• Treatment in special populations
  • REDPINE: remdesivir in people with renal impairment hospitalized for COVID-19 pneumonia
  • Remdesivir and readmission for COVID-19 in immunocompromised patients
  • Molnupiravir vs nirmatrelvir plus ritonavir for COVID-19 with hematologic malignancy
• Management of patients with severe disease
  • RECOVERY: higher-dose vs standard-dose corticosteroids for hospitalized patients with COVID-19
  • Real-world study of tocilizumab vs baricitinib for severe COVID-19
• Novel antivirals
  • Ensitrelvir
  • Bemnifosbuvir
•  Novel vaccines
  • NB2155
  • AZD2816/AZD1222
  • qNIV/CoV2373
  • GRT-R910
  • NVX-CoV2373 in people with HIV

Faculty:  
Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI
Professor of Microbial Diseases
Centre for Experimental Pathogen Host Research
University College Dublin
Dublin, Ireland

Content based on an online CME/CE program supported by independent educational grants from Gilead Sciences, Inc. and Novavax.  

Link to full program: 
bit.ly/3niXGJ6

Link to downloadable slides: 
bit.ly/3LUFejG